We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
K V Pharma CL A | NYSE:KVA | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that the firms are investigating legal claims against the officers and Board of Directors of K-V Pharmaceutical Company (“KV Pharmaceutical” or “KV-A”) (NYSE: KV-A) (NYSE: KV-B) related to potential securities violations by KV Pharmaceutical between February 14, 2011 and April 4, 2011 (the “Class Period”).
If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at patrick@powerstaylor.com, or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.
It has been alleged that during the Class Period, KV Pharmaceutical and certain of its officers and directors made materially false and misleading statements or failed to disclose material information related to the company’s business and operations in violation of the Securities Exchange Act of 1934. Specifically, the complaint alleges that defendants misrepresented that the Food and Drug Administration (FDA) had granted KV Pharmaceutical the exclusive distribution rights over "Makena," a drug used to prevent miscarriages, and that the FDA would enforce those rights by preventing KV Pharmaceutical’s competitors from distributing generic formulations of the drug. The complaint further alleges that defendants failed to disclose that the drug’s $1,500 price actually would reduce the availability of Makena to low-income and other at-risk groups. It’s alleged that the defendants’ false statements cause KV Pharmaceutical’s stock to trade at artificially inflated prices during the Class Period.
The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.
Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.
1 Year K V Pharma CL A Chart |
1 Month K V Pharma CL A Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions